Ardelyx Launches Multi-Year LPGA Partnership to Educate on IBS-C
Ardelyx signed a multi-year deal as pharmaceutical marketing partner of the LPGA Tour to champion awareness of irritable bowel syndrome with constipation (IBS-C) in women, who comprise over 90% of patients. It will leverage digital and social media, onsite events and player ambassadors in the 2026 season to educate patients.
1. Multi-Year LPGA Marketing Partnership
Ardelyx has entered a multi-year agreement as the exclusive pharmaceutical marketing partner of the Ladies Professional Golf Association (LPGA) Tour. The deal positions Ardelyx across LPGA events and platforms, reflecting a first-of-its-kind corporate affiliation designed to raise the company’s profile among women golf enthusiasts.
2. Focus on IBS-C Awareness
The collaboration specifically targets irritable bowel syndrome with constipation (IBS-C), a condition affecting mental health, work productivity and personal relationships. With women constituting more than 90% of IBS-C patients, Ardelyx and the LPGA aim to break stigma and foster proactive health conversations.
3. Activation and Initiatives
Ardelyx will deploy a 360-degree marketing approach throughout the 2026 season, including original digital and social content, onsite experiences, premium hospitality and player ambassador programs. Additional partnership activities and campaign details will be rolled out at key LPGA tournaments to drive patient education and engagement.